CAR-T细胞作为大B细胞淋巴瘤二线治疗:范式转变?
综述解读3项比较CAR-T细胞疗法与自体干细胞移植的随机3期试验,探讨CAR-T作为适合的难治或早期复发大B细胞淋巴瘤患者二线治疗新标准。
要点
- 复发或难治大B细胞淋巴瘤标准治疗为大剂量化疗后自体干细胞移植(ASCT),仅适用于化疗敏感且适合的患者。
- 因治疗强度大,该方案仅半数患者可行;因化疗耐药,仅四分之一适合移植患者成功。
- 靶向CD19的CAR-T细胞疗法已获批用于大B细胞淋巴瘤三线治疗,部分患者获持久缓解。
核心结论
- 综述解读3项随机3期试验的设计与结果,探讨CAR-T细胞疗法作为适合的难治或早期复发大B细胞淋巴瘤患者二线治疗潜在新标准的可能性。
研究设计与样本
- 综述类:解读3项比较CAR-T细胞疗法与ASCT的随机3期试验的设计与结果。
主要发现
- 标准治疗为大剂量化疗后ASCT(若化疗敏感且适合),因治疗强度仅半数患者可行,因化疗耐药仅四分之一适合移植患者成功。
- 靶向CD19的CAR-T细胞疗法已获批用于大B细胞淋巴瘤三线治疗,部分患者获持久缓解。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The standard of care treatment strategy for patients with relapsed or refractory large B-cell lymphoma (LBCL) has been high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) if chemotherapy sensitive in suitable patients. Because of treatment intensity, this approach has only been feasible in half of patients and because of chemotherapy resistance has only been successful in a quarter of transplant-eligible patients. Chimeric antigen receptor (CAR) T-cell therapy, using genetically modified autologous T cells targeting CD19, has been approved for third-line therapy of LBCL and has been associated with durable remissions in a proportion of patients. In this review, we interpret the design and results of 3 randomized phase 3 trials comparing CAR T-cell therapy and ASCT and their implications for CAR T-cell therapy as a potential new standard of care for second-line treatment in appropriate patients with refractory or early relapsing LBCL.
引用
- Westin J, Sehn LH. CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift? Blood. 2022. PMID: 35240677. doi:10.1182/blood.2022015789
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。